Skip to main content

Drug Safety

RheumNow Podcast square
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-OPTIMISE:…
Video: The PsA SpA Paradox of Choice

Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized T

Dr. John Cush RheumNow

3 months 2 weeks ago
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.  Professor …
PSA068.jpg
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of…
joint.wrist_.pain_.CTS_.Carpal.jpg
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require…
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract O

Dr. John Cush RheumNow

3 months 2 weeks ago
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 ) Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021. https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
RT @MeralElRamahiMD: OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASD

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
RT @MeralElRamahiMD: ⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 m

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
×